Clinical trial
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage…
NCT03703297 · AstraZeneca, Industry · Active, not recruiting
Key facts
| NCT number | NCT03703297 |
|---|---|
| Title | Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy |
| Official title | A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC) |
| Acronym | ADRIATIC |
| Lead sponsor | AstraZeneca, Industry |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug, Other |
| Interventions | Durvalumab, Tremelimumab, Placebo |
| Enrollment | 730 |
| Start date | Sep 27, 2018 |
| Primary completion | Jan 15, 2024 |
| Completion | Oct 23, 2026 |
| First posted | Oct 11, 2018 |
| Last update posted | Nov 21, 2025 |
| Countries | Argentina, Belgium, Canada, China, Czechia, Germany, India, Italy, Japan, Netherlands, Poland, Russia and 7 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: